The Germline SH2B3(rs111340708) Splicing Variant Drives Intron Retention and Protein Instability by Impacting Clinical Outcomes in Core Binding Factor AML
A common genetic variant impairs a protein that controls blood cell production, offering new clues for predicting leukemia risk and developing targeted therapies.
The SH2B3 gene, also known as LNK, encodes an adaptor protein that negatively regulates key hematopoietic signaling pathways, including JAK-STAT, MAPK, and PI3K/AKT, thereby maintaining hematopoietic homeostasis. The reported conclusion is: Collectively, these findings identify a common germline splicing polymorphism as a novel mechanism contributing to SH2B3 functional impairment in AML and highlight the potential relevance of non-coding variants in leukemia pathogenesis, with possible implications for risk stratification and future therapeutic strategies.
What the study was
- Study design
- Observational cohort study
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Hematological oncology
Why it surfaced
Retained for Hematologic malignancies; score reflects the available PubMed abstract, study design, clinical relevance, and unmet need.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.